Reduced IL-17 expression and slower NAFLD progression are caused by overexpression of miRNA-26a, which is partly mediated by IL-6 inhibition (He et al., 2017). This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.